Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.8 USD | +3.13% | -2.55% | -1.41% |
Feb. 14 | Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024 | |
Feb. 14 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.41% | 15.59M | |
+25.61% | 660B | |
+25.03% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+13.06% | 219B | |
-9.65% | 196B | |
+6.63% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- AYTU Stock
- News Aytu BioPharma, Inc.
- Aytu Biopharma : BioScience Acquires Global License to Enzastaurin From Rumpus Therapeutics